Scottish HTA rejects Zytiga and BindRen; four others accepted
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium (SMC) has made decisions on six drugs, four of which it believes warrant reimbursement including Pfizer's Bosulif (bosutinib) and Celgene's Abraxane (paclitaxel). However, Janssen's Zytiga (abiraterone acetate) and Mitsubishi Tanabe Pharma's BindRen did not make the cut.